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Abstract
Background: Findings from both epidemiological and basic research point to the possibility that
NSAIDS impede the deterioration in schizophrenia.
Methods: To study the efficacy of acetylsalicylic acid we will perform a randomized placebo
controlled double-blind add-on trial of 80 inpatients and outpatients with schizophrenia,
schizophreniform or schizoaffective disorder. Patients will be 1:1 randomized to either 3 months
1000 mg acetylsalicylic acid per day or 3 months placebo, in addition to their regular antipsychotic
treatment. All patients will receive pantoprazole treatment for gastroprotection. The outcomes of
this study are 3-month change in psychotic and negative symptom severity, cognitive function, and
several immunological parameters.
This trial may (1) yield a new (adjuvant) therapy for schizophrenia and (2) add to the knowledge on 
the pathogenesis of this major psychiatric disorder.
Background
Despite several advances in the treatment of schizophre-
nia, currently available pharmacotherapy does not change
the course of illness or prevent functional deterioration in
a substantial number of patients. Therefore, research
efforts into alternative or adjuvant treatment options are
needed. In this project we will empirically investigate the
effect of the anti-inflammatory drug acetylsalicylic acid as
an add-on to regular antipsychotic therapy on the symp-
toms of schizophrenia.
There are several observations and theoretical considera-
tions that support the hypothesis that anti-inflammatory
drugs can be effective in antagonizing the process under-
lying the clinical deterioration in schizophrenia. In
numerous epidemiological and clinical studies an inverse
relationship between schizophrenia and rheumatoid
arthritis has been demonstrated, i.e. these conditions
rarely coexist in one person [1,2]. A possible explanation
for this relationship implies that the use of anti-inflam-
matory drugs by patients with rheumatoid arthritis pro-
tects them against the development or progression of
schizophrenia. This hypothesis is supported by the obser-
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only rheumatoid arthritis is far less frequent among
patients with schizophrenia, but also other musculoskele-
tal conditions commonly treated with anti-inflammatory
drugs[3]. These conditions were osteoarthritis of the knee,
hip and spine, low back pain, and intervertebral disc dis-
orders.
The hypothesis of the effectiveness of anti-inflammatory
drugs in schizophrenia is also supported by more basic
science findings. A prominent hypothesis concerning the
pathogenesis of schizophrenia implicates dysfunction of
the N-methyl-D-aspartate acid (NMDA) receptor [4]. This
hypothesis suggests that in schizophrenia progressive
excitotoxic neuronal cell death occurs via disinhibition of
glutamatergic projections to hippocampal and cortical
areas [5]. In this respect, prostaglandins may play an
important role in two ways: (1) because they are interme-
diaries in the postsynaptic signal transduction cascade of
cells with NMDA-type glutamate receptors and (2) by
potentiating glutamatergic transmission by inhibiting
astrocytic reuptake of glutamate. Both mechanisms can
potentiate excitotoxic cell death[6]. As non-steroidal anti-
inflammatory drugs (NSAIDs) inhibit prostaglandin syn-
thesis through the inactivation of cyclooxygenase, they
may be of therapeutic value in schizophrenia. This mech-
anism may also play a role in the recently confirmed
inverse relation between long-term use of NSAIDs and the
risk of Alzheimer's disease[7]. The therapeutic potential of
acetylsalicylic acid is further suggested by the results of an
experiment performed by Grilli et al., who reported that
acetylsalicylic acid and its metabolite sodium salicylate
protected against neurotoxicity elicited by the excitatory
amino acid glutamate in rat neuronal cultures and hip-
pocampal slices[8].
Also according to the immunological hypothesis of schiz-
ophrenia, intervention with acetylsalicylic acid may have
favourable effects. Activation of the immune system in
schizophrenic patients is evident from many studies dem-
onstrating dysregulated pro-inflammatory cytokines like
interleukin (IL)-1, IL-2, and in particular IL-6 and tumor
necrosis factor (TNF)-alpha [9]. The importance of the
immune system in the pathophysiology of schizophrenia
is indirectly supported by the evidence that many antipsy-
chotics can act as immunomodulators [10,11]. Recently,
decreased T helper-1 (TH-1) related immune parameters
were found in patients with schizophrenia[11] and a shift
to TH-2 like immune reactivity in a subgroup of schizo-
phrenic patients has been hypothesized[12]. Prostaglan-
din E2 is known to enhance the production of TH2
cytokines via inhibition of the production of IL-12 by
antigen presenting cells such as monocytes [13]. There-
fore, it is conceivable that the shift towards TH-2 cytokine
production in schizophrenia will be counteracted by inhi-
bition of prostaglandin formation by acetylsalicylic acid.
Also because IL-12 enhances production of TH-1
cytokines, we expect that administration of acetylsalicylic
acid will also result in more TH-1 activity (e.g. γ-interferon
production) relative to TH-2 activity (e.g. IL-4 produc-
tion). The resulting correction of the T-helper cell imbal-
ance may eventually reduce the symptoms of
schizophrenia. Accordingly, we postulate that the greatest
effect of acetylsalicylic acid will therefore be observed in
those individuals with the highest relative TH-2 reactivity,
i.e. the lowest IFN-γ/IL-4 ratio. It should be noted that
peripheral expression of cytokines may be a reflection of
the pattern of cytokine production in the brain, where
cytokines are produced by glial cells, astrocytes etc., and
that, additionally, anti-inflammatory cytokines of periph-
eral origin may signal the brain, thereby contributing to
the symptoms of schizophrenia. In order to monitor the
effect of the proposed immunosuppressive treatment with
acetylsalicylic acid and to get more insight in the possible
role of cytokines in the clinical symptoms of schizophre-
nia, we intend to determine TH-1 and TH-2 cytokines as
well as IL-6 (general immune activation), produced by
peripheral blood cells before, during and after the treat-
ment with acetylsalicylic acid.
Alternatively, NSAIDS may ameliorate symptoms of schiz-
ophrenia by affecting neuronal membrane phospholip-
ids. As suggested by Horrobin a decreased incorporation
of arachidonic acid and docosahexaenoic acid into mem-
brane phospholipids combined with an increased
removal of these essential fatty acids hamper normal neu-
rodevelopment and adult neuronal functioning [14].
Each of these abnormalities may be related to an altered
activity of phospholipase A2. As acetylsalicylic acid inhib-
its phospholipase A2 this NSAID may yield clinical
improvement in schizophrenia[1].
Finally, a recent study showed cyclo-oxygenase hyperac-
tivity in platelets of schizophrenic patients[15]. If also
present in the brain this further implicates acetylsalicylic
acid as a potential therapeutic agent for schizophrenia.
As cyclooxygenase-1 and cyclooxygenase-2 are both con-
stitutively expressed in the brain [16], both the older
COX-1 NSAIDS such as acetylsalicylic acid and indometh-
acin and the newer selective COX-2 NSAIDS such as
celecoxib may theoretically impede the pathologic proc-
ess in schizophrenia. We are aware of only one clinical
trial that examined the potential therapeutic role of
NSAIDS in schizophrenia. It demonstrated a beneficial
effect of the COX-2 inhibitor celecoxib as an add-on ther-
apy during five weeks on schizophrenia psychopathology
in 50 patients[17]. We decided to study the efficacy of the
non-selective classical NSAID acetylsalicylic acid because
of its neuroprotective effect in rat neuronal cultures and,Page 2 of 6
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Trials 2006, 7:31 http://www.trialsjournal.com/content/7/1/31in view of the epidemiological inverse relation between
schizophrenia and rheumatoid arthritis, because of its
past widespread use in the treatment of rheumatoid
arthritis.
Research questions
Does 1000 milligrams of acetylsalicylic acid daily reduce
symptoms of schizophrenia? Is this effect modified by ini-
tial relative TH-2 reactivity?
Study objectives
To determine the effect of three months additional treat-
ment with acetylsalicylic acid on positive, negative and
cognitive symptoms as well as immunological parameters
in patients treated with antipsychotics for schizophrenia.
A secondary objective is to examine whether this effect is
modified by initial relative TH-2 reactivity.
Design and methods
General
We will perform a randomized, placebo-controlled, dou-
ble-blind multicenter trial of 80 inpatients and outpa-
tients with schizophrenia, schizophreniform or
schizoaffective disorder.
Inclusion criteria
To be included in the study one has to give written
informed consent, be diagnosed with schizophrenia,
schizophreniform or schizoaffective disorder according to
DSM-IV, aged between 18 and 55 years old, with disease
duration less than 10 years. All participants have to be
clinically stable, meaning no change in dose of antipsy-
chotic drugs 2 weeks before inclusion. At randomisation
all participants need to have a score of at least 60 on the
total score of the Positive and Negative Syndrome Scale
(PANSS) with two scores of at least 4. For safety reasons
participants are not allowed to have a contraindication
for, or be hypersensitive to acetylsalicylic acid or panto-
prazole, have a significant somatic illness or be pregnant.
Participants are not allowed to use corticosteroids or
chronically use of nonsteroidal anti-inflammatory drugs
(NSAIDs) or platelet inhibitors. Persons with drugs
dependencies are not allowed to participate.
Screening
Patients will be recruited at the Department of Psychiatry
of the University Medical Center Utrecht, 'Symfora Amers-
foort', 'Psychiatric Center AMC/de Meren, Amsterdam',
'Spatie Apeldoorn', 'Stichting de Geestgronden', 'Adhesie
Deventer', 'RIAGG Amersfoort' and the 'Delta pychiatric
hospital'. If the treating responsible psychiatrist considers
a patient eligible for study, his diagnosis will be con-
firmed according to the Diagnostic and Statistical Manual
of Mental Disorders fourth edition (DSM-IV) using the
Comprehensive Assessment of Symptoms and History
(CASH). The PANSS will be filled out and the remaining
inclusion criteria will be checked by taking medical his-
tory and performing a general physical examination.
Finally, venous blood will be taken for the assessment of
immunological parameters.
Informed consent
The trial will be conducted in agreement with the princi-
ples of the Declaration of Helsinki (Edinburgh 2000). The
investigator will explain the benefits and risks of partici-
pation in the study to each subject and will provide an
informed consent form approved by the ethical review
board of the University Medical Center Utrecht. The
patient is then asked to sign the form prior to inclusion
into the study. Data from this study will be treated confi-
dentially and publication of the results of this study will
be performed anonymously.
Placebo run-in and adherence
A placebo run-in procedure will be set up to test the par-
ticipant's adherence behavior in advance of the actual
study. Patients meeting the inclusion criteria will be asked
to take the add-on study medication (only placebo, no
pantoprazole) during two weeks and will be asked to
return the empty blisters to the researcher for administra-
tive reasons. Only participants showing greater than 80%
adherence (more than 80% of medication taken) will be
randomized. During the trial the participants and their
close relatives/friends will be informed about the impor-
tance of continuation of taking the study medication and
returning the empty blisters to the researcher. Adherence
will be checked by counting the returned empty blisters
and determining plasma salicylic acid at months two and
three. All participants will be kindly asked not to use any
drugs such as marijuana or hashish within 24 hours
before visit.
Baseline assessments
As patients will be randomized in strata of relative TH-2
reactivity a blood sample will be taken at the beginning of
the placebo run-in in order to have the immunological
parameters determined by the time of randomization. At
most one week before randomization, the severity of base-
line psychotic symptoms will be assessed using the
PANSS. In addition, a short cognitive test battery focusing
on verbal learning and motor performance (e.g. Califor-
nia verbal learning test, Purdue Peg Board test, trail mak-
ing test, HQ-Continues Performance test) will be
administered.
Randomized intervention
Patients will be randomized in a 1:1 ratio to either supple-
mentation of acetylsalicylic acid or placebo in addition to
their current antipsychotic treatment. Randomization will
be performed in strata of psychiatric center (tertiary orPage 3 of 6
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delineated by the median IFN-γ/IL-4 ratio. To this end a
computer-generated list will be produced with allocation
codes in random order, balanced in the four strata by
using permuted blocks. The aspirin dose is based on a
trade-off between a dose that has a relatively low risk of
gastro-intestinal toxicity in young persons, and the dose
that is presumed to be anti-inflammatory, the latter being
adopted from therapeutic doses used in the treatment of
musculo-skeletal disorder[18]. Placebo will be identically
packaged, looking and tasting tablets. For optimal gastro
protection, all patients (also those randomized to pla-
cebo) will be given 40 milligrams of pantoprazole
daily[19].
Concomitant medication
As an analgesic the patients will be emphatically advised
to take acetaminophen instead of acetylsalicylic acid or
other NSAIDS. A record of all medication taken will be
kept during the entire trial.
Adverse reactions
Acetylsalicylic acid use may cause dyspeptic complaints,
ulcer disease and gastrointestinal bleeding. However, due
to its strong association with high age (odds ratio 1.04 per
year[20]), we expect that the risk of ulcer or serious bleed-
ing is considerably lower than 1% per year that was
observed in persons over 60 years of age taking similar
doses of aspirin[21]. Further, all patients will be given 40
milligrams pantoprazole daily which has shown to reduce
the risk of NSAID induced gastrointestinal problems con-
siderably[19]. Nevertheless, at every follow-up visit the
participants will be asked about epistaxis, hematemesis,
melena, rectal bleeding and hematuria. Further, dyspeptic
complaints will be systematically recorded at every visit
using an 8-item self-administered questionnaire [22].
Patients will be urged to stop taking study medication one
week in advance of molar extractions or similar surgical
procedures and to continue not before one week after the
procedure. In case of medical emergencies the initial care
will be managed by the general practitioner as in usual
care, if possible after consultation of the investigator, or
the person taking medical responsibility for the partici-
pants in this study (Prof. dr R.S. Kahn). At a later stage the
investigator will consult the treating psychiatrist and the
patient's general practitioner whether continuation in the
trial is reliable.
Study outcomes
The primary outcome of this trial is the 3-month change
in positive and negative symptoms on the total PANSS
score. Secondary outcomes are the 3-month change in the
PANSS subscales, cognitive symptoms, immunological
parameters (γ-interferon, IL-4, IL-6 and IL-12), and psy-
choactive medication taken during the trial.
Follow-up assessments
At one, two, and three months, and in case of withdrawal
from the study, the severity of positive and negative symp-
toms will be reassessed using the PANSS. The cognitive
tests will be repeated at three months or at study discon-
tinuation. Blood samples will be taken at 2 and 3 months,
or at withdrawal, for determination of the Aspirin levels.
All assessments will be performed blind to medication
status. The overview of the visits can be seen in table 1.
Immunological measurements
To analyze the effect of the treatment on cytokine produc-
tion, we will determine the in vitro capacity of peripheral
blood mononuclear cells to produce cytokines.
Heparinized blood (15 ml) will be drawn before, after
two and after three months of treatment, or at earlier with-
drawal. Peripheral blood mononuclear cells will be iso-
lated by centrifugation of Ficoll isopaque. T cell cytokine
Table 1: Overview of assessments/interventions
Start of run-in Baseline 1 Month 2 Months 3 Months (@)
Informed Consent X - - - -
Screening X - - - -
Pregnancy test X - - - -
Randomization - X - - -
Immunological parameters X - - X X
Blood for DNA isolation X - - - -
Aspirin concentration - - - X X
PANSS - X X X X
CASH (+) X - - - -
Cognitive tests - X - - X
Adverse events - - X X X
Co-medication X X X X X
Compliance - X X X X
@ or withdrawal
+ if previous CASH is longer than 6 months agoPage 4 of 6
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anti-CD28 and anti-CD2 monoclonal antibodies and
supernatants will be collected after 48 hours of culture. In
addition, adherent cells (monocytes/macrophages) will
be stimulated for 24 hours with lipopolysaccharide to
induce IL-6 and IL-12 production. Cytokine levels in cul-
ture supernatants will be analyzed by ELISA. In vivo
cytokine production will be analyzed by determining
cytokine levels in plasma samples obtained at the same
time points. In addition, blood will be stored for future
research possibilities on the immunological or genetic
aspects of schizophrenia, schizoaffective and schizo-
phreniform disorders, after permission of the patients (in
the informed consent form).
Withdrawal from the study
A patient must be withdrawn from the study when judged
necessary by the responsible psychiatrist or when the
patient withdraws his/her informed consent. In these
instances all outcomes should be assessed.
Study size
The planned number of patients to be included in this
trial is 80, 40 in each arm. This is sufficient to show a sta-
tistically significant difference between the intervention
arms of effect size (Cohen's d) ≥ 0.66 for the change in
total PANSS score from baseline to last follow-up. It is
based on an alpha of 0.05, a power (1-beta) of 0.8 and a
two-sided unpaired t-test. Further, we accounted for 10%
withdrawal. It should be noted that the power of the
repeated measures analyses is considerably higher.
Data analysis
The statistical significance of the difference in the change
in total PANSS score, its subscores, cognitive functions,
immunological parameters from baseline to last follow-
up between the arms and psychoactive medication will be
tested using a two-sided unpaired t-test and its magnitude
will be supplied with a 95% confidence interval. In addi-
tion, all outcomes will be analyzed as dependent variables
in repeated measurements analyses with treatment arm as
the independent variable. To study whether the poten-
tially beneficial effect of acetylsalicylic acid is modified by
initial relative TH-2 reactivity, we will repeat the analyses
in strata of IFN-γ/IL-4 ratio The analyses will primarily be
'intention-to-treat'. In addition, a per protocol analysis
will be performed on those who showed more than 90%
adherence. If despite randomization important baseline
differences in prognostic factors exist, adjustments will be
made by including the corresponding variables as inde-
pendents in the multivariable models. Finally, the change
in psychopathological symptoms will be related to the
change in immunological parameters using multivariable
regression models. In these analyses adjustments for con-
founders will be made when appropriate.
Duration
We estimate that recruitment of patients will take 1 year.
Follow-up will last 3 months. Assuming that data analysis
and reporting require around 9 months, the total duration
of the trial will be approximately 2 years.
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